Component 1 — Revolutionizing Clinical Trials with ACT-SMART

Testing new treatments is key to progress in prostate cancer. Unfortunately, the current model for actsmart_coupleconducting clinical trials — evaluating the effectiveness of therapies on human subjects — leaves something to be desired. Only one drug can be tested in each trial, and the time and cost
involved reduce the total number of novel approaches that can be evaluated and slow the pace
of discovery.
Dramatic scientific advances in molecular biology now offer the opportunity for much better strategies. IPCR faculty members aim to exploit these opportunities and establish a program that follows a new, dynamic and flexible model: the adaptive clinical trial.
In the adaptive clinical trial, researchers use what they learn from each patient to make real-time adjustments as the trial proceeds. In this way, time and resources are diverted from unsuccessful strategies to more promising ones, enhancing both the pace of research and the quality of
patient care.
Through our program, called Adaptive Clinical Trials-Survey, Measure and Redirect Therapy, or ACT-SMART, we will be able to carry out studies that evolve in response to the information they are generating. We will initially target patients with advanced, metastatic prostate cancer. Later, we will expand activities to include men with high-risk, localized disease.
By more rapidly improving our understanding of prostate cancer and its variation in individual patients, ACT-SMART trials will speed the development of strategies that match treatments (and secondary prevention approaches) to a patient’s needs.